Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Hearing Loss Patients
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The randomized, double-blind, placebo-controlled trial demonstrated that a single intratympanic injection of 0.3 mg OTO-413, a sustained…
Read More
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, has announced the completion of patient enrollment in the Phase 2 clinical trial of OTO-313 in tinnitus. The randomized, double-blind, placebo-controlled trial enrolled 153 patients with persistent, unilateral tinnitus of at least moderate severity (target…
Read MoreOtonomy Reports Corporate and Product Pipeline Update
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. Consistent with previously stated timing, the company expects to report results for the Phase 2a cohort of OTO-413 in hearing loss patients early in…
Read MoreOtonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, has announced the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty. The randomized, double-blind, placebo-controlled study cohort will enroll approximately 30 hearing loss patients…
Read More
Otonomy Presents Encouraging Preclinical Data for OTO-825 Gene Therapy Hearing loss Treatment
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. OTO-825 is an AAV-mediated gene therapy targeting the gap junction beta-2 (GJB2) gene developed under…
Read MoreOtonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-413 in subjects with speech-in-noise hearing difficulty. The randomized, double-blind, placebo-controlled trial demonstrated that a single intratympanic injection of OTO-413, a sustained exposure…
Read More
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in Hair Cell Regeneration Program
SAN DIEGO, CALIFORNIA — Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, has announced an exclusive license agreement with Kyorin Pharmaceutical Co., Ltd. that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss. Under the terms of…
Read More
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 for Tinnitus
SAN DIEGO, CALIFORNIA — Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced positive top-line results from the Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity. The exploratory efficacy cohort of the trial included 31 evaluable patients randomized to a single…
Read More
Otonomy and AGTC Present Preclinical Results for GJB2 Gene Therapy Hearing Loss Program
SAN DIEGO, CALIFORNIA — Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation (AGTC) that support the selection of a product candidate for development as a treatment for gap junction beta-2 (GJB2) deficiency, the most…
Read MoreOtonomy Initiates Phase 1/2 Clinical Trial of OTO-313 for Tinnitus
SAN DIEGO, CALIFORNIA — Otonomy has announced the initiation of a Phase 1/2 clinical trial of OTO-313 in patients with tinnitus. The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus. OTO-313 is said to be a…
Read More